Home > Business > Industry

Celltrion's Truxima becomes first Korea-developed biosimilar to lead U.S. market

Published: 07 Apr. 2026, 17:26

Celltrion logo on the company's Songdo plant in Incheon [CELLTRION]

Korean biopharmaceutical company Celltrion's biosimilar, which is used to treat blood cancers, claimed the largest share of prescriptions in the United States in February.

The biosimilar, known as Truxima, accounted for 35.8 percent of U.S. prescriptions in its category during the month, the company said in a press release on Tuesday. This marks the first time that a biosimilar developed by a Korean firm has led the U.S. market.

According to Celltrion, the growing demand in the United States, the world's biggest pharmaceutical market, for its biosimilar products will help it achieve its earnings targets for the year.

It aims to post an operating profit of 1.7 trillion won ($1.1 billion) on sales of 5.3 trillion won in 2026, up from 1.16 trillion won and 4.16 trillion won, respectively, last year.

The company also plans to increase the share of new biosimilars in total sales to 70 percent this year, up from 54 percent in 2025.

Celltrion has been expanding its global biosimilar portfolio, with the number of approved products rising to 11 from six. It aims to launch 18 biosimilars by 2030 and 41 by 2038.

Its only original drug, Zymfentra, is currently sold in the United States for autoimmune diseases and marketed as Remsima SC in Europe and other regions.

Yonhap